Evidence Explorer · MS-N242 · Multimodal nutrition and exercise · disability-free survival · Appraised November 5, 2026
The NEXTAC randomized trial found that a 12-week nutrition-and-exercise support program did not prolong disability-free survival in older adults starting systemic treatment for advanced pancreatic or non-small-cell lung cancer.
Evidence at a glance
- Benefit signal: No demonstrated improvement in disability-free survival or reported secondary outcomes.
- Certainty: Moderate for the tested multimodal program; the trial was randomized but modest in size and combined nutrition with exercise.
- Risk context: High completion suggests feasibility among selected participants, but frailty, cachexia and treatment toxicity require individualized targets.
- Cancer-control relevance: Did not test tumor response as a primary endpoint and did not demonstrate improved survival or cancer control.
What was studied
The multicenter study randomized 131 adults, with 129 included in the analysis, to NEXTAC (66) or usual care (65). Median age was approximately 76 years. Participants had advanced pancreatic cancer or non-small-cell lung cancer and were starting systemic therapy.
The 12-week program combined nutrition and exercise consultations. Among 64 people who received the intervention, 98.4% of planned sessions were completed.
What the study found
Median disability-free survival was 478 days with NEXTAC and 499 days with usual care: hazard ratio 0.970 (95% CI 0.642 to 1.465; p=0.884). Reported secondary outcomes also did not differ.
Because the intervention was multimodal, the study cannot isolate the independent effect of exercise or nutrition.
What this does not establish
The trial does not rule out benefit from differently dosed, longer, more supervised or diagnosis-specific programs. It also does not justify assuming that high session completion improves function, survival or tumor control.
Safety and practical context
Rapid weight loss, dehydration, obstruction risk, severe fatigue, falls and treatment complications should be assessed before increasing activity or changing intake.
For pancreatic cancer, pancreatic enzyme insufficiency, diabetes and malabsorption can change the nutrition plan. Exercise targets should be coordinated with oncology, nutrition and rehabilitation teams.
Questions for the care team
- Is weight loss driven by low intake, malabsorption, inflammation or treatment effects?
- What function matters most—walking, transfers, strength or independence?
- Would supervised rehabilitation or symptom-focused nutrition support better match current needs?
Sources and identifiers
Funding and conflicts: Not fully verified from the accessible abstract.
Source access and dates: Primary abstract was appraised; complete protocol deviations, adverse events and funding disclosures were not fully verified. Sources checked November 5, 2026. Last literature search November 5, 2026.
Educational evidence summary, not individualized medical advice. Exercise around cancer treatment should be adapted to symptoms, blood counts, bone health, cardiopulmonary status, surgical restrictions and the treating team’s guidance.
